NEW YORK — Metabolon has signed a multiyear drug development alliance with Germany's Merck KGaA, the companies said on Monday.
Under the terms of the deal, Metabolon will apply its Precision Metabolomics liquid chromatography-mass spectrometry global metabolomics platform — which identifies pharmacodynamic, efficacy, and response biomarkers and tracks changes in biological pathways — to undisclosed early-stage drug development programs across therapeutic areas at Merck.
Additional terms were not disclosed.
In early 2018, Morrisville, North Carolina-based Metabolon was selected to perform large-scale metabolomic profiling on samples from US veterans as part of the US Department of Veterans Affairs' Million Veteran Program.